H. pylori infection reduces severity of Salmonella-induced colitis: Research

NewsGuard 100/100 Score

Helicobacter pylori, a common stomach bacterium, reduced the severity of inflammation of the colon caused by Salmonella in mice, according to research from U-M Medical School scientists.

More than half the people in the world are infected with H. pylori, although it is very unusual to find it in the United States. But this research shows there may be an inflammation control benefit to hosting the H. pylori infection, says Peter Higgins, M.D., Ph.D., M.Sc., lead author of the study published last week in the journal Inflammatory Bowel Diseases.

"If we have evolved to live with certain bugs, maybe there is a reason," said Higgins, assistant professor of gastroenterology in U-M's Department of Internal Medicine. "This research demonstrates that having H. pylori in your stomach could have beneficial immune effects in other parts of the body."

In the study, mice were infected with H. pylori, allowed to develop immune tolerance for a month, and then infected with Salmonella, which induces the inflammatory bowel disease colitis. The data provided the first evidence that H. pylori infection in the stomach alters the immunological environment of the lower gastrointestinal tract and reduced the severity of Salmonella-induced colitis.

"This was surprising because H. pylori infects the stomach, not the colon. It appears to have a more global effect on the gut immune system," says John Kao, M.D., senior author of this study and assistant professor in U-M's Department of Internal Medicine.

"But it may explain why people in regions with lots of H. pylori infection — such as Asia and Africa — get fewer inflammatory bowel diseases, like ulcerative colitis and Crohn's disease."

It also may explain why H. pylori infection is so common, Higgins says. Salmonella was historically a rampant fatal infection that caused the plague of Athens, which led to rise of Sparta. It also likely led to the early death of Alexander the Great. So it would make sense that many humans carry the H. pylori bacteria, if it truly reduces the severity of inflammation caused by Salmonella, Higgins says.

The H. pylori infection is now more commonly found in developing countries or those with poor sanitation, where Salmonella and inflammatory bowel diseases are more common. Most people contract H. pylori in their first seven years of life, most commonly through exposure to feces.

Higgins does not recommend that inflammatory bowel patients should be infected with H. pylori, however. In the U.S., H. pylori infection is treated with antibiotics because it can lead to stomach ulcers or cancer, even though most people don't notice they have it.

"There may be a reason we co-exist with H. pylori. Maybe we should not be so quick to get rid of it in patients who do not have stomach ulcers," Higgins says, adding that this may be especially true in places where Salmonella remains a common threat.

"It would be reasonable for researchers to look at whether H. pylori infection is associated with reduced severity of other gut infections like cholera or Clostridium difficile. Many more studies are needed, however, to see if H. pylori could actually prevent inflammatory bowel disease."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New research pinpoints key pathways in prostate cancer's vulnerability to ferroptosis